glp-1 agonist eli lilly Medscape Novo Nordisk vs Eli Lilly:
Description
Primary prevention of cardiovascular and heart failure events with SGLT2 Inhibitors, GLP-1 receptor Agonists, and their combination in type 2 diabetes
This scenario highlights the tension between ensuring drug availability and maintaining rigorous safety standards
Complete information on authors, methodology and conflicts of interest is available in the published paper
Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes
Muscle preservation is important regardless of which GLP-1 agonist you use
